{"id":31842,"date":"2026-07-07T16:00:00","date_gmt":"2026-07-07T14:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=cb38d2bbd425b2e1b676cbf956f083f0"},"modified":"2026-07-07T16:00:00","modified_gmt":"2026-07-07T14:00:00","slug":"molecular-targeting-technologies-presents-first-clinical-validation-of-the-evans-blue-platform-demonstrating-up-to-15-day-tumor-retention-using-approximately-12-5-of-the-radioactivity-required-for-co","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=31842","title":{"rendered":"Molecular Targeting Technologies Presents First Clinical Validation of the Evans Blue Platform, Demonstrating Up to 15-Day Tumor Retention Using Approximately 12.5% of the Radioactivity Required for Conventional PRRT"},"content":{"rendered":"

\nLargest Reported Clinical Dataset for an Albumin-Binding Radiotherapeutic Supports the Evans Blue Platform as a Foundational Technology for Next-Generation Targeted Radiopharmaceuticals<\/b><\/p><\/a><\/a>

WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI), a clinical-stage biotechnology company developing next-generation radiopharmaceutical platform technologies, today announced that clinical data from 81 patients\u2014the largest reported clinical dataset for an albumin-binding radiotherapeutic\u2014will be presented at the 5th Targeted Radiopharmaceuticals Summit.<\/b> The dataset provides what the Company believes is the first clinical validation of its proprietary Evans Blue (EB) platform, a reversible albumin-binding technology designed to enhance the pharmacokinetics and therapeutic performance of targeted radiopharmaceuticals.<\/p>

\nThe presentation supports an emerging paradigm in radiopharmaceutical oncology: optimizing pharmacokinetics may become as important as discovering new molecular targets. The Evans Blue platform is designed to enhance the therapeutic performance of existing and next-generation targeted radiopharmaceuticals across multiple validated molecular targets.<\/p>

\nClinical imaging and dosimetry demonstrated tumor retention for up to 15 days, approximately eight-fold greater tumor uptake<\/b>, and efficient therapeutic radiation delivery while requiring only approximately 12.5%<\/b> of the cumulative administered radioactivity used in conventional peptide receptor radionuclide therapy (PRRT). These findings suggest that improving pharmacokinetics through reversible albumin binding may substantially improve therapeutic efficiency while reducing the administered radioactivity required to achieve comparable tumor radiation delivery.<\/p>

\nKey clinical and preclinical findings include:<\/b><\/p>